Belantamab mafodotin for the treatment of multiple myeloma.

• Wang, B. ^[1] ; Wu, C. ^[1] ; Zhong, Q. ^[2] ; Ling, J. ^[1] ; Wu, Z. ^[1] ; Yu, B. ^[1] ; Gao, X. ^[1] ; Zeng, H. ^[1] ; Yang, D.-H. ^[3]
  1. [1] First Affiliated Hospital of Jinan University

     First Affiliated Hospital of Jinan University

     China

     
  2. [2] Department of Hematology, Guangdong Second Provincial General Hospital, Guangzhou, China
  3. [3] Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St.John's University, Queens, New York City, NY, United States

  Mostrar afiliaciones +
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 57, Nº. 11, 2021, págs. 653-663
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Multiple myeloma is the second most common hematologic malignancy worldwide. Despite the growing number of available therapeutic options and advances in the treatment since the 2000s, relapse of multiple myeloma is inevitable. Currently, the main therapeutic agents for multiple myeloma treatment include proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies and others. Patients who relapse or are refractory to the above-mentioned treatments have poor prognosis. B-cell maturation antigen (BCMA) is a cell-surface receptor which is expressed on the membrane of multiple myeloma cells, but absent on naive and memory B cells, making it an ideal target for multiple myeloma treatment. Belantamab mafodotin (GSK-2857916) is a first-in-class BCMA antibody-drug conjugate with an overall response rate of 32% in the phase II clinical trial DREAMM-2, which is a phase II study designed to investigate the efficacy and safety of belantamab mafodotin in relapsed/refractory patients with multiple myeloma. In August 2020, based on the results of this pivotal DREAMM-2 study, the U.S. Food and Drug Administration (FDA) approved belantamab mafodotin as a monotherapy for relapsed/refractory multiple myeloma. Thereafter, the European Medicines Agency (EMA) also approved this indication. Although belantamab mafodotin has demonstrated single-agent activity in relapsed/refractory multiple myeloma, further studies to evaluate its efficacy and its combinational use with other drugs are necessary and ongoing.